Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, September 30, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Profusa, Inc. Common Stock
Market Cap
$1.88M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.89M
Return on Equity (ROE)
-1677.17%
TTM Avg
-443.00%
3Y Avg
-318.43%
5Y Avg
-234.70%
Market Cap
$1.86M
Return on Equity (ROE)
-615.03%
TTM Avg
-210.38%
3Y Avg
-268.95%
5Y Avg
-212.66%
Market Cap
$1.85M
Return on Equity (ROE)
N/A
TTM Avg
-239.06%
3Y Avg
-695.85%
5Y Avg
-455.08%
Market Cap
$1.93M
Return on Equity (ROE)
-509.36%
TTM Avg
-212.22%
3Y Avg
-233.92%
5Y Avg
-323.18%
Market Cap
$1.84M
Return on Equity (ROE)
-30.92%
TTM Avg
247.31%
3Y Avg
-294.42%
5Y Avg
-190.41%
Market Cap
$1.64M
Return on Equity (ROE)
-91.52%
TTM Avg
-77.16%
3Y Avg
-63.00%
5Y Avg
-74.35%
Market Cap
$2.17M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
Market Cap
$2.18M
Return on Equity (ROE)
N/A
TTM Avg
642.41%
3Y Avg
-629.18%
5Y Avg
-444.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profusa, Inc. Common Stock (PFSA) | $1.88M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.89M | -1677.17% | -443.00% | -318.43% | -234.70% |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.86M | -615.03% | -210.38% | -268.95% | -212.66% |
| Tenon Medical, Inc. (TNON)vs › | $1.85M | N/A | -239.06% | -695.85% | -455.08% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.93M | -509.36% | -212.22% | -233.92% | -323.18% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.84M | -30.92% | 247.31% | -294.42% | -190.41% |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | -91.52% | -77.16% | -63.00% | -74.35% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.17M | -1160.10% | -528.10% | -389.86% | -336.02% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.18M | N/A | 642.41% | -629.18% | -444.57% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | -169.64% | 97.92% | 65.28% | 65.28% |
ROE
N/A
ROA
-4123.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-09-30 | -170.06% |
